House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study

BMC Public Health

Gulshan Bhatia¹  Andrea Polesky¹  Alicia H Chang² 

[1] Department of Medicine, Division of Mycobacterial Diseases and International Health, Santa Clara Valley Medical Center, 751 S. Bascom Ave, San Jose, CA 95128, USA;Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, 300 Pasteur Drive, Grant Building S-101, MC-5107, Stanford, CA 94305, USA

关键词: Rifampin;    Hepatitis;    House calls;    Public health nurses;    Community health workers;    Isoniazid;    Adherence;    LTBI;    Latent tuberculosis infection;   

Others  :  1161728
DOI  :  10.1186/1471-2458-13-894

 received in 2013-03-25, accepted in 2013-09-25,  发布年份 2013

【 摘 要 】

Background

Patient adherence to isoniazid (INH) monotherapy for latent tuberculosis infection (LTBI) has been suboptimal despite its proven efficacy. Various strategies have been studied to improve adherence, but all have been based at a clinic or treatment program. At the Santa Clara Valley Tuberculosis Clinic, it was our practice to refer a subset of high-risk LTBI patients to the Public Health Department for monthly follow-up at home instead of at the clinic. Our goal was to assess whether house calls by community health workers and public health nurses affected INH adherence or frequency of adverse effects.

Methods

We retrospectively studied 3918 LTBI patients who received INH. At the discretion of the treating physician, 986 (25.2%) received house calls instead of clinic follow-up. Home-based follow-up included language translation, medication delivery, assessment of compliance with pill counts, monitoring for adverse effects, and active tracking of noncompliant patients. We assessed differences in patient characteristics, treatment completion, and reasons for treatment discontinuation between patients followed at home versus in the clinic. Multivariate analyses to address possible referral bias or confounding were performed using logistic regression.

Results

More patients followed with house calls completed INH treatment (90% home versus 73.2% clinic). This was the case across all subgroups of patients, including those with historically the lowest adherence: patients from correctional and rehabilitation facilities (77.8% home versus 46.9% clinic), postpartum women (86.4% home versus 55.6% clinic), and patients aged between 18 and 35 years (87% home versus 63.1% clinic). After adjusting for age, place of birth, referral category (TB contacts/skin test converters, correctional/rehabilitation patients, postpartum women, tuberculin positive patients from other screening), and prescribed INH regimen duration (9 versus 6 months), home-based follow-up of LTBI patients was a significant predictor of treatment completion (AOR 2.94, 95% CI: 2.33, 3.71). Patients followed at home were 21% more likely to complete therapy (ARR 1.21, p<0.001). Risk of adverse effects was similar between the two types of follow-up.

Conclusion

Home-based follow-up of LTBI patients taking isoniazid was associated with improved treatment completion and no increase in adverse effects regardless of patient characteristics or prescribed duration of INH therapy.

【 授权许可】

   
2013 Chang et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Targeted tuberculin testing and treatment of latent tuberculosis infection: American thoracic society MMWR Recomm Rep 2000, 49(RR-6):1-51.
• [2]Ferebee SH: Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibliotheca tuberculosea 1970, 26:28-106.
• [3]Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial: international union against tuberculosis committee on prophylaxis Bull World Health Organ 1982, 60(4):555-564.
• [4]Comstock GW: How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 1999, 3(10):847-850.
• [5]Healthy people 2010, vol. two, second edn. Washington DC, USA: US Department of Health and Human Services; 2000.
• [6]Hirsch-Moverman Y, Daftary A, Franks J, Colson PW: Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008, 12(11):1235-1254.
• [7]Horsburgh CR, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, et al.: Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010, 137(2):401-409.
• [8]Tulsky JP, Hahn JA, Long HL, Chambers DB, Robertson MJ, Chesney MA, Moss AR: Can the poor adhere? Incentives for adherence to TB prevention in homeless adults. Int J Tuberc Lung Dis 2004, 8:83-91.
• [9]Last JP, Kozakiewicz JM: Development of a pharmacist-managed latent tuberculosis clinic. Am J Health Syst Pharm 2009, 66(17):1522-1523.
• [10]White MC, Tulsky JP, Goldenson J, Portillo CJ, Kawamura M, Menendez E: Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med 2002, 162(9):1044-1050.
• [11]Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, et al.: An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174(8):935-952.
• [12]Zhang J, Yu KF: What’s The relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA: the journal of the American Medical Association 1998, 280(19):1690-1691.
• [13]Daly LE: Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol 1998, 147(8):783-790.
• [14]Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75(4):800-802.
• [15]Rose DN, Schechter CB, Silver AL: The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. JAMA: the journal of the American Medical Association 1986, 256(19):2709-2713.
• [16]Young H, Wessolossky M, Ellis J, Kaminski M, Daly JS: A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in Central Massachusetts. Clin Infect Dis 2009, 49(3):424-427.
• [17]Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, et al.: Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006, 166(17):1863-1870.
• [18]Holland DP, Sanders GD, Hamilton CD, Stout JE: Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009, 179(11):1055-1060.
• [19]Menzies D, Al Jahdali H, Al Otaibi B: Recent developments in treatment of latent tuberculosis infection. Indian J Med Res 2011, 133:257-266.
• [20]Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, et al.: Three months of rifapentine and isoniazid for latent tuberculosis infection. The New England journal of medicine 2011, 365(23):2155-2166.
• [21]Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE: New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine 2011, 365(1):11-20.
• [22]Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection Morbidity and mortality weekly report 2011, 60(48):1650-1653.
• [23]Holland D, Sanders G, Hamilton C, Stout J: Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS ONE 2011, 6(7):e22276-e22276.
• [24]Portilla J, Jorda P, Esteban J, Sanchez-Paya J, Merino E, Boix V, Grupo de Estudio Protocolo INH: Directly observed treatment of latent tuberculosis infection: comparative study of two isoniazid regimens. Enfermedades infecciosas y microbiologia clinica 2003, 21(6):293-295.
• [25]Schumann A, Nyamathi A, Stein JA: HIV risk reduction in a nurse case-managed TB and HIV intervention among homeless adults. J Health Psychol 2007, 12(5):833-843.
• [26]Nyamathi A, Nahid P, Berg J, Burrage J, Christiani A, Aqtash S, Morisky D, Leake B: Efficacy of nurse case-managed intervention for latent tuberculosis among homeless subsamples. [Article]. Nurs Res 2008, 57(1):33-39.
• [27]Dobler C, Marks G: Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic. PLoS ONE 2012, 7(11):e48900-e48900.
• [28]Nolan CM, Goldberg SV, Buskin SE: Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA : the journal of the American Medical Association 1999, 281(11):1014-1018.